GENFIT S.A. ACLF– Advancing a multi-target therapeutic strategy GENFIT to host a scientific event on November 8, 2026 to outline its ACLF strategy and unveil a comprehensive clinical data package supporting the advancement of nangibotide into Phase 2 in this indication Three poster presentations will provide new insights into the role of inflammation and immune dysregulation in acute liver failure, as well as further clinically relevant evidence of nitazoxanide's anti-inflammatory activity, supporting its development in ACLF Management to present at dedicated scientific meeting with NACSELD, a leading North American research consortium in cirrhosis and ACLF, to deepen scientific engagement MASH Diagnostics – Unlocking the opportunity as MASH...
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。